CD274 and neoplasm: Circulating tumor cells (CTCs) offer insights into the tumor of origin and metastatic sites, with studies showing that melanoma patients with PD-L1-positive CTCs are significantly more likely to respond to pembrolizumab compared to those without detectable PD-L1-positive CTCs.